万邦德(002082) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥315,110,184.08, a decrease of 26.58% compared to ¥429,172,675.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,201,816.26, down 47.29% from ¥28,838,483.33 year-on-year[5] - The basic earnings per share decreased by 46.57% to ¥0.0249 from ¥0.0466 in the same period last year[5] - Total operating revenue decreased to ¥315,110,184.08 from ¥429,172,675.52, representing a decline of approximately 26.6% year-over-year[19] - Net profit for the period was ¥11,227,654.31, down from ¥24,958,440.91, indicating a decline of approximately 55.1% year-over-year[19] - Total comprehensive income attributable to the parent company's owners was CNY 16,503,593.60, a decrease from CNY 28,166,335.28 in the previous period, representing a decline of approximately 41.6%[21] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0466, indicating a decrease of about 46.5%[21] Cash Flow - The net cash flow from operating activities was -¥17,285,740.15, a decline of 117.05% compared to ¥101,357,363.89 in the previous year[5] - The company reported a decrease in sales expenses to ¥41,035,894.57 from ¥68,543,940.69, reflecting a cost-cutting strategy[19] - Net cash flow from operating activities was negative CNY 17,285,740.15, compared to positive CNY 101,357,363.89 in the previous period, reflecting a significant decline[22] - Cash inflow from investment activities totaled CNY 2,872,578.72, an increase from CNY 1,967,181.53 year-over-year[22] - Cash outflow from investment activities was CNY 25,332,665.92, down from CNY 166,170,288.90, indicating a reduction of approximately 84.8%[22] - Net cash flow from financing activities was negative CNY 59,487,257.84, compared to positive CNY 27,980,960.68 in the previous period, showing a reversal in cash flow[22] - The ending balance of cash and cash equivalents was CNY 44,302,664.88, down from CNY 183,656,176.46, a decrease of about 76.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,271,069,770.54, a decrease of 1.30% from ¥4,327,397,080.53 at the end of the previous year[5] - Total liabilities decreased to ¥1,501,478,651.87 from ¥1,570,954,359.63, showing a reduction of about 4.4%[18] - Non-current liabilities totaled ¥332,227,294.64, an increase from ¥254,681,402.98, representing a growth of approximately 30.4%[18] - As of the end of the reporting period, the company's total current assets amounted to approximately CNY 1.75 billion, a decrease from CNY 1.80 billion at the beginning of the period[16] Government Support and Subsidies - The company received government subsidies amounting to ¥27,691,508.52, which positively impacted the financial results[6] Research and Development - Research and development expenses were ¥12,774,780.81, slightly down from ¥13,058,050.61, indicating a continued commitment to innovation despite revenue challenges[19] - Wanbangde Pharmaceutical received approval from the National Medical Products Administration for the supplement application of Cefaclor granules, which is considered to have passed the consistency evaluation of generic drug quality and efficacy, enhancing market competitiveness[11] - The company obtained FDA approval for clinical trials of WP107 (Huperzine A oral solution) for treating generalized myasthenia gravis and WP103 (Huperzine A injection) for treating neonatal hypoxic-ischemic encephalopathy, marking a significant step in new drug development[12] - The FDA granted orphan drug designation for Mecobalamin for the treatment of Amyotrophic Lateral Sclerosis (ALS), providing various incentives for drug development and commercialization in the U.S. market[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,646, with the largest shareholder holding 31.37% of the shares[9] - The company completed the repurchase of 5 million shares in March 2022, which were subsequently canceled due to the inability to complete the employee stock ownership plan within the effective period[15]